In vitro and animal PK/PD models

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

Volumn , Issue , 2014, Pages 23-44

  Craig, William A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Animal models; Animal peritonitis models; Animal pneumonia models; Hollow fiber dialysis models; In vitro dialysis models; In vitro dilution models; Murine thigh infection model

Indexed keywords

EID: 84926396198     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-75613-4_2     Document Type: Chapter

References (100)

1. Acred P, Hunter PA, Mizen L, Rolinson G.N. (1970) Alpha-amino-para-hydroxybenzyl penicillin (BRL 2333), a new broad-spectrum semisynthetic penicillin: in vivo evaluation. Antimicrob Agents Chemother 1:416-422
2. Acred P, Ryan DM, Sowa M.A., Watts C.M. (1981) The in-vivo antibacterial activity of ceftazidime (Gr 20263) - a comparison with other new beta-lactam antibiotics and gentamicin. J Antimicrob Chemother 8(Suppl B):247-255
3. Ahmed A, Paris MM, Trujillo M, Hickey S.M., Wubbel L., Shelton SL, McCracken GJ Jr (1997) Once-daily gentamicin therapy for experimental Escherichia coli meningitis. Antimicrob Agents Chemother 41:49-53
4. Andes D, Craig W.A. (1998a) In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 42:2375-2379
5. Andes DR, Craig W.A. (1998b) Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 27:47-50
6. Andes DR, Craig W.A. (1999) Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin N Am 13:595-618
7. Andes DR, Craig W.A. (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261-268
8. Andes D, Craig W.A. (2005) Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11(Suppl 6):10-17
9. Andes A, Craig W.A. (2007) In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 51:1633-1642
10. Azoulay-Dupuis E., Bedos JP, Vallee E, Hardy D.J., Swanson RN, Pocidalo J.J. (1991a) Antipneumococcal activity of ciprofloxacin, ofoxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis 163:319-324
11. Azoulay-Dupuis E., Bedos JP, Vallee E, Pocidalo J.J. (1991b) Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. J Antimicrob Chemother 28:45-53
12. Bakker-Woudenberg IAJM, de Jong-Hoederop JY, Michel MF (1979) Efficacy of antimicrobial chemotherapy in experimental rat pneumonia: effects of impaired phagocytosis. Infect Immun 25:366-375
13. Bakker-Woudenberg I.A., ten Kate MT, Goessens WH, Mouton J.W. (2006) Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob Agents Chemother 50:2919-2925
14. Bergan T, Carlsen IB, Fuglesang J.E. (1980) An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions. Infection 8:S103-S108
15. Blaser J (1985) In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130
16. Blaser J, Stone BB, Groner M.C., Zinner S.H. (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054-1060
17. Bonapace CR, Friedrich LV, Bosso J.A., White R.L. (2002) Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob Agents Chemother 46:3574-3579
18. Boutoille D, Jacqueline C, Le Mabecque V, Potel G, Caillon J. (2009) In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection. Int J Antimicrob Agents 33:417-420
19. Craig WA, Andes D.R. (2008) In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh- and lung-infection models. Antimicrob Agents Chemother 52: 3492-3496
20. Craig WA, Gudmundsson S. (1996) Postantibiotic effect (Chapter 8). In: Lorian V (ed) Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins, Baltimore, MD, pp 296-329
21. Crandon JL, Kuti JL, Nicolau D.P. (2010) Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother 54:5115-5119
22. Davis SD (1975) Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa. Antimicrob Agents Chemother 8:50-53
23. den Hollander J.G., Fuursted K, Verbrugh H.A., Mouton J.W. (1998) Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 42:749-754
24. Drusano GL, Fregeau C, Liu W., Brown DL, Louie A. (2010) Impact of burden of granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother 54:4368-4372
25. Drusano GL, Johnson DE, Rosen M, Standiford H.C. (1993) Pharmacodynamics of a fluoroquinolones antimicrobial agent in a neutropenic rat model of pseudomonas sepsis. Antimicrob Agents Chemother 37:483-490
26. Dudley MN, Blaser J, Gilbert D., Zinner S.H. (1990) Significance of "extravascular" protein binding fir antimicrobial pharmacodynamics in an in vitro capillary model of infection. Antimicrob Agents Chemother 34:98-101
27. Eagle H, Fleishman R, Musselman A.D. (1950) Effect of schedule of administration on the therapeutic efficacy of penicillin. Am J Med 9:280-299
28. Firsov AA, Vostrov SN, Kononenko O.V., Zinner SH, Portnov Y.A. (1999) Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 43:498-502
29. Firsov AA, Vostrov SN, Lubenko I.Y., Drlica K., Portnoy YA, Zinner S.H. (2003) In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47:1604-1613
30. Frimodt-Moller N., Bentzon MW, Thompson V.F. (1986) Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 154:511-517
31. Garrett ER, Miller G.H. (1965) Kinetics and mechanism of action of antibiotics on microorganisms. 3: inhibitory action of tetracycline and chloramphenicol on Escherichia coli established by total and viable counts. J Pharm Sci 54:427-431
32. Garrison MW, Vance-Bryan K, Larson T.A., Toscano JP, Rotschaefer J.C. (1990) Assessment of the effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 34:1925-1931
33. Garrod LP (1948) The bactericidal action of streptomycin. Br Med J 1:382-386
34. Gavalda J, Lopez P, Martin T., Gomis X, Ramirez JL, Azuaje C, Almirante B., Pahissa A. (2002) Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis. Antimicrob Agents Chemother 46:378-384
35. Gerber AU, Craig W.A. (1981) Growth kinetics of respiratory pathogens after short exposures to ampicillin and erythromycin in vitro. J Antimicrob Chemother 8(Suppl B):81-91
36. Gerber AU, Vastola AP, Brandel J, Craig W.A. (1982) Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis 146:691-697
37. Gerber AU, Craig WA, Brugger H-P, Feller C, Vastola A.P., Brandel J. (1983) Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytic mice. J Infect Dis 147:910-917
38. Grasso S, Meinardi G, de Carneri I, Tamassia V. (1978) New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13:570-576
39. Hanberger H, Nilsson LE, Kihlstrom E, Maller R. (1990) Postantibiotic effect of ß-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. Antimicrob Agents Chemother 34:102-106
40. Hulten K, Rigo R, Gustafsson I., Engstrand L. (1996) New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob Agents Chemother 40:2727-2731
41. Hunter PA, Rolinson GN, Witting D.A. (1973) Comparative activity of amoxicillin and ampicillin in experimental infection in mice. Antimicrob Agents Chemother 4:285-293
42. Kang SL, Rybak M.J. (1995) Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother 39:1505-1511
43. Keil S, Weidemann B. (1995) Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrob Agents Chemother 39:1054-1058
44. Kim A, Banevicius MA, Nicolau D.P. (2008) In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 52:2497-2502
45. Knudsen JD, Fuusted K, Raber S., Espersen F, Frimodt-Moller N (2000) Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae and Staphylococcus aureus infections. Antimicrob Agents Chemother 44:1247-1254
46. Knudsen JD, Odenholt I, Erlendsdottir H., Gottfredsson M, Cars O, Frimodt-Moller N, Espersen F., Kristinsson KG, Gudmundsson S. (2003) Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother 47:2499-2506
47. Koomanachal P, Crandon JL, Banevicius M.A., Peng L., Nicolau D.P. (2009) Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 53:5060-5063
48. Kover A, Dalla Costa T, Derendorf H. (1997) Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci 86:52-56
49. Kunst WM, Mattie H. (1978) Cefazolin and cephradine relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli. J Infect Dis 137:391-401
50. Ledergerber B, Blaser J, Luthy R. (1985) Computer-controlled in-vitro simulation of multiple dosing regimens. J Antimicrob Chemother 15(Suppl A):169-173
51. 7 CFU in opposite thighs. Antimicrob Agents Chemother 57(3):1434-1441
52. Leggett JE, Fantin B, Ebert S., Totsuka K, Vogelman B, Calame W., Mattie H, Craig W.A. (1989) Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159:281-292
53. Leggett JE, Ebert S, Fantin B., Craig W.A. (1991) Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 74(Suppl):179-184
54. Liu P, Muller M, Grant M., Webb AI, Obermann B, Derendorf H. (2002) Interstitial tissue concentrations of cefpodoxime. J Antimicrob Chemother 50(Suppl):19-22
55. Lorian V, Zak O, Sutter J., Bruecher C. (1985) Staphylococci in vitro and in vivo. Diag Microbiol Infect Dis 3:433-444
56. Lorian V, Ernst J, Amaral L. (1989) The post-antibiotic effect defined by bacterial morphology. J Antimicrob Chemother 23:485-491
57. Louie A, Vanscoy BD, Heine HS III, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, Drusano GL (2012) Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob Agents Chemother 56:513-517
58. Lowdin E, Odenholt I, Cars O. (1998) In vitro studies of pharmacodynamic properties of vancomycin and against Staphylococcus aureus and Staphylococcus epidermitis. Antimicrob Agents Chemother 42:2739-2744
59. Lutsar I, Ahmed A, Friedland I.R., Trujillo M., Wubbel L, Olsen K, McCracken GH Jr (1997) Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporinresistant pneumococcal meningitis. Antimicrob Agents Chemother 41:2414-2417
60. Lutsar I, Friedland IR, Wubbel L, McCoig C.C., Jafri HS, Ng W, Ghaffar F, McCracken GH Jr (1998) Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporinresistant pneumococcal meningitis. Antimicrob Agents Chemother 42:2650-2655
61. MacKenzie FM, Gould IM, Chapman D.G., Jason D. (1994) Comparison of methodologies used in assessing the postantibiotic effect. J Antimicrob Chemother 34:223-230
62. Maglio D, Ong C, Barevicius G.Q., Nightingale CH, Nicolau D.P. (2007) Determination of the in vivo profile of cefepime against extended-spectrum-ß-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 48:1941-1947
63. McDonald PJ, Wetherall BL, Pruul H. (1981) Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 3:38-44
64. Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38:931-936
65. Nicolau DP, Onyeji CO, Zhong M, Tessier P.R., Banevicius MA, Nightingale C.H. (2000) Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 44:1291-1295
66. Noel AR, Bowker KE, MacGowan A.P. (2005) Pharmacodynamics of moxifloxacin against anaerobes studies in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 49:4234-4239
67. Nuermberger E, Helke K, Bishai W.R. (2005) Low-dose aerosol model of pneumococcal pneumonia in the mouse model: utility for evaluation of antimicrobial efficacy. Int J Antimicrob Agents 26:497-503
68. Odenholt I, Holm SE, Cars O. (1989) Effects of benzylpenicillin on Streptococcus pyogenes during the postantibiotic phase in vitro. J Antimicrob Chemother 24:147-156
69. Odenholt I, Lowdin E, Cars O. (2007) Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 51:3311-3316
70. Odenholt-Tornqvist I., Lowdin E, Cars O. (1992) Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother 36:1852-1858
71. Pennington JE, Stone R.M. (1979) Comparison of antibiotic regimens for treatment of experimental pneumonia due to pseudomonas. J Infect Dis 140:881-889
72. Reeves DS (1985) Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyzer: results of experiments with ciprofloxacin. J Antimicrob Chemother 15(Suppl A):159-167
73. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel BM (1989) Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 10:878-887
74. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF (1986) Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 30:403-408
75. Sanberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Moller N (2010) Intraand extracellular activity of linezolid against Staphylococcus aureus in vitro and in vivo. J Antimicrob Chemother 65:962-973
76. Schmidt LH, Walley A. (1951) The influence of the dosage regimen on the therapeutic effectiveness of penicillin in experimental lobar pneumonia. J Pharmacol Exp Ther 103:479-488
77. Schmidt LH, Walley A, Larson R.D. (1949) The influence of the dosing regimen on the therapeutic activity of penicillin G. J Pharmacol Exp Ther 96:258-268
78. Scoriano F, Ponte C, Nieto E., Parra A. (1996) Correlation on in vitro activity and pharmacokinetics parameters with in vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. J Antimicrob Chemother 38:227-236
79. Selbie FR (1954) Comparison of sodium and procaine penicillin in treatment of experimental staphylococcal infection in mice. BMJ 1:1350-1351
80. Selbie FR, Simon R.D. (1952) Virulence of mice to Staphylococcus pyogenes: its measurement and its relation to certain in vitro properties. Br J Exp Pathol 33:315-326
81. Shah PM, Junghanns W, Stille W. (1976) Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus. Dtsch Med Wochenschr 101:325-328
82. Smimova MV, Vostrov SN, Strukova E.V., Dovzhenko SA, Kobrin MB, Portnoy YA, Zinner S.H., Firsov A.A. (2009) The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother 64:815-820
83. Stearne LE, Gyssens IC, Goessens W.H., Mouton JW, Oyen WJ, van der Meer JW, Verbrugh HA (2001) In vivo efficacy of trovafloxacin against Bacteroides fragilis in a mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Antimicrob Agents Chemother 45:1394-1401
84. Stearne LE, Goessens WH, Mouton J.W., Gyssens I.C. (2007) Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development or murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob Agents Chemother 51:3605-3611
85. Tam VH, Ledesma KR, Chang K.T., Wang TY, Quinn J.P. (2009) Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis 64:166-171
86. Tano E, Cars O, Lowdin E. (2005) Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vivo kinetic model. J Antimicrob Chemother 56:240-242
87. Tateda K, Takashima K, Miyazaki H., Matsumoto T, Hatori T, Yamaguchi K. (1996) Noncompromized penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 40:1520-1525
88. Tauber MG, Doroshow CA, Hackbarth C.J., Rusnak MG, Drake TA, Sande M.A. (1984a) Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis 149:568-574
89. Tauber MG, Zak O, Scheld W.M., Hengstler B., Sande M.A. (1984b) The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis 149:575-583
90. Toothaker RD, Welling PG, Craig W.A. (1982) An in vitro model for the study of antibacterial dosage regimen design. J Pharm Sci 71:861-864
91. Tsaganos T, Skiadas I, Koutoukas P., Adamis T, Baxevanos N, Tzepi I., Pelekanou A, Giamarellos-Bouboulis EJ, Giamarellou H, Kanellakoulou K. (2008) Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillinresistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 62:381-383
92. Unadkat JD, Bartha F, Sheiner L.B. (1986) Simultaneous modeling of pharmacokinetic and pharmacodynamic with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 40:86-93
93. van't Wout JW, Linde I, Leijh PC, van Furth R (1989) Effect of radiation, cyclophosphamide, and etoposide (VP-16) on number of peripheral blood and peritoneal leukocytes in mice under normal conditions and during acute inflammatory reaction. Inflammation 13:1-14
94. Vogelman B, Craig W.A. (1986) Kinetics of antimicrobial activity. J Pediatr 108:835-840
95. Vogelman B, Gudmundsson S, Leggett J., Turnidge J, Ebert S, Craig W.A. (1988a) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847
96. Vogelman B, Gudmundsson S, Turnidge J., Craig W.A. (1988b) The in vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 175:287-298
97. Woodnut G, Berry V. (1999) Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 43:29-34
98. Wright DH, Gunderson BW, Hovde L.B., Ross GH, Ibrahim KH, Rotschafer J.C. (2002) Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob Agents Chemother 46:1561-1563
99. Zinner SH, Husson M, Klastersky J. (1981) An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. J Infect Dis 144:583-587
100. Zuluaga AF, Salazar BE, Rodriquez C.A., Zapata AX, Agudelo M, Vesga O. (2006) Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 6:55